Overview

The Effect Effect of Empagliflozin on Oxidative Stress in Patients With Type 2 Diabetes

Status:
Completed
Trial end date:
2020-01-22
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the effect of empagliflozin on oxidative stress in patients with type 2 diabetes. The association is examined by comparing the difference in oxidative modifications before and after 14 days treatment with 25 mg empagliflozin compared to placebo treatment. The study is randomised, double-blinded, and placebo controlled. Each treatment group consists of 17 males with type 2 diabetes. Oxidative modifications are measured by urinary excretion of 8-oxo-7,8-dihydro-2'-deoxyguanosine and 8-oxo-7,8-dihydroguanosine. A student t-test will be performed to compare the drug treatment with placebo. The results will be published in a peer-review journal.
Phase:
Phase 2
Details
Lead Sponsor:
Henrik Enghusen Poulsen
Collaborators:
University Hospital, Gentofte, Copenhagen
University of Copenhagen
Treatments:
Empagliflozin